WO2023242384A1 - Crystalline form of ibrutinib - Google Patents

Crystalline form of ibrutinib Download PDF

Info

Publication number
WO2023242384A1
WO2023242384A1 PCT/EP2023/066201 EP2023066201W WO2023242384A1 WO 2023242384 A1 WO2023242384 A1 WO 2023242384A1 EP 2023066201 W EP2023066201 W EP 2023066201W WO 2023242384 A1 WO2023242384 A1 WO 2023242384A1
Authority
WO
WIPO (PCT)
Prior art keywords
temperature
ibrutinib
water
alcohol
crystalline form
Prior art date
Application number
PCT/EP2023/066201
Other languages
French (fr)
Inventor
Primož BENKIC
Ana BERGANT SIMONCIC
Sara HROVAT
Dejan Klement
Monika KUFNER
Original Assignee
Krka, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka, D.D., Novo Mesto filed Critical Krka, D.D., Novo Mesto
Publication of WO2023242384A1 publication Critical patent/WO2023242384A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to crystalline form of ibrutinib, designated as Form KI, and processes for its preparation.
  • Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK).
  • BTK Bruton's tyrosine kinase
  • the chemically name of ibrutinib is l-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl]piperidin-l-yl]prop- 2-en-l-one and it has the following formula:
  • WO 2013/184572 discloses amorphous form, crystalline forms and solvates of ibrutinib, designated as Form A, Form B, Form C, Form D, Form E and Form F.
  • CN 103694241 discloses crystalline form A of ibrutinib.
  • CN 103923084 discloses anhydrous forms, hydrates and solvates of ibrutinib, designated as form II, form III, form IV, form V, form VI, form VII and form VIII.
  • WO 2015/081180 discloses a crystalline form of ibrutinib, designated as Form I.
  • WO 2015/145415 discloses anhydrous forms, hydrates and solvates of ibrutinib, designated as Form III, Form IV, Form V, Form VI, Form VII, Form VIII and Form IX.
  • WO 2016/025720 discloses crystalline forms and solvates of ibrutinib designated as Form G, Form J and Form K.
  • WO 2016/079216 and WO 2016/160598 disclose solvates of ibrutinib.
  • WO 2016/139588 discloses crystalline forms and solvates of ibrutinib designated as Form DI, Form Dla, Form D2, Form D2a, Form D3, Form D4, Form D5, Form D6, Form D7, Form D8, Form D9, Form D10, Form Dl l, Form D12 and Form D13.
  • WO 2017/029586 discloses crystalline forms of ibrutinib, designated as Form SI, Form S2, Form S3, Form S4, and an amorphous form, designated as Form Al.
  • CN 105646484 discloses a crystalline form B of ibrutinib.
  • CN 105646498 discloses a crystalline form F of ibrutinib.
  • WO 2016/160604 discloses ibrutinib co-crystals with organic acids.
  • Known crystalline forms of ibrutinib show different properties regarding dissolution, stability, processing, etc.
  • a new crystalline form of ibrutinib and a process for preparing it Particularly, there is a need for a new crystalline form of ibrutinib having a good balance between dissolution properties and stability properties.
  • a new crystalline form of ibrutinib having good handling and/or processing properties Furthermore, there is a need for a new crystalline form of ibrutinib having good handling and/or processing properties.
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 20 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more
  • step a) 10 to 30 ml of alcohol is used per gram of ibrutinib, preferably 10 to 20 ml of alcohol is used per gram of ibrutinib, more preferably 10 to 15 ml of alcohol is used per gram of ibrutinib.
  • step c) The process according to any one of items (8) to (11), wherein in step c) a ratio between alcohol and water is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1: 1 to 1:2, most preferably 1: 1.5.
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 d) optionally, adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 to 45 °C,
  • step a) 5 to 30 ml of solvent mixture is used per gram of ibrutinib, preferably 5 to 20 ml of solvent mixture is used per gram of ibrutinib, more preferably 5 to 10 ml of solvent mixture is used per gram of ibrutinib.
  • step a) a volume ratio between alcohol and water is from 10: 1 to 1: 1, preferably from 8: 1 to 2: 1, more preferably from 6: 1 to 4: 1, most preferably 5: 1.
  • step a) ibrutinib is dissolved at temperature from 45 °C to 70 °C, preferably at temperature from 50 °C to 60 °C, more preferably at temperature from 50 °C to 55 °C.
  • Figure 1 illustrates an X-ray powder diffraction (XRPD) pattern of a crystalline Form KI of ibrutinib.
  • Figure 2 illustrates a Differential Scanning Calorimetry (DSC) thermogram of a crystalline Form KI of ibrutinib.
  • Figure 3 illustrates SEM of a crystalline Form KI of ibrutinib.
  • so called 'kinetic' polymorphs shows better dissolution rate that is advantageous during formulation technology and afford several simplification in technology and composition to prepare efficient final dosage formulation.
  • so called kinetic polymorphs are difficult to produce in polymorphic pure form in robust manner, they often exhibit weak crystallographic and chemical stability and special solvent systems and technologies are required. That is drawback that need to be overcome to make kinetic polymorph useful and profitable for production on industrial scale.
  • new crystalline form of ibrutinib Form KI shows improved dissolution rates compared to thermodynamically more stable forms, like form A, but at the same time it shows good chemical stability and polymorphic stability what is not the case for other kinetic forms of ibrutinib with low crystallinity or even amorphous.
  • Crystalline Form KI of ibrutinib has good filterability that afford good washing of filtered wet cake, good purity and efficient drying resulting in residual organic solvents below limit of detection and very low moisture content. Additionally, crystalline Form KI of ibrutinib shows favorable morphology in view of good handling, particularly good flowability.
  • First aspect of the present invention is a crystalline Form KI of ibrutinib.
  • the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3 ⁇ 0.1°, 8.8 ⁇ 0.1°, 11.7 ⁇ 0.1°, 13.1 ⁇ 0.1°, 14.9 ⁇ 0.1°, and 16.8 ⁇ 0.1° 2Theta.
  • the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3 ⁇ 0.1°, 8.8 ⁇ 0.1°, 11.2 ⁇ 0.1°, 11.7 ⁇ 0.1°, 13.1 ⁇ 0.1°, 14.9 ⁇ 0.1°, I5.2 ⁇ 0.I°, 16.8 ⁇ 0.1°, and 18.5 ⁇ 0.1° 2Theta.
  • XRPD X-ray powder diffraction
  • the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3 ⁇ 0.1°, 8.8 ⁇ 0.1°, 11.2 ⁇ 0.1°, 11.7 ⁇ 0.1°, 13.1 ⁇ 0.1°, 14.9 ⁇ 0.1°, I5.2 ⁇ 0,I°, 16.8 ⁇ 0.1°, 18.5 ⁇ 0.1°, 20.1 ⁇ 0.1°, 21.7 ⁇ 0.1°, and 23.8 ⁇ 0.1° 2Theta.
  • XRPD X-ray powder diffraction
  • the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3 ⁇ 0.1°, 5.7 ⁇ 0.1°, 6.6 ⁇ 0.1°, 8.4 ⁇ 0.1°, 8.8 ⁇ 0.1°, 10.8 ⁇ 0.1°, 11.2 ⁇ 0.1°, 11.7 ⁇ 0.1°, 11.9 ⁇ 0.1°, 13.1 ⁇ 0.1°, 13.7 ⁇ 0.1°, 14.9 ⁇ 0.1°, 15.2 ⁇ 0.1°, 15.9 ⁇ 0.I°, 16.6 ⁇ 0.1°, 16.8 ⁇ 0.1°, 17.7 ⁇ 0.1°, 18.5 ⁇ 0.1°, 19.0 ⁇ 0.1°, 20.1 ⁇ 0.1°, 20.9 ⁇ 0.1°, 21.7 ⁇ 0.1°, 22.0 ⁇ 0.1°, 23.0 ⁇ 0.1°, 23.8 ⁇ 0.1°, 24.5 ⁇ 0.1°, 25.7 ⁇ 0.1°, 26.8 ⁇ 0.1°, 28.1 ⁇ 0.1°, 29.7 ⁇ 0.1°, 30.6 ⁇ 0.1°, 31.4 ⁇ 0.1°, and 32.0 ⁇ 0.1° 2Theta
  • the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern substantially the same as shown in Figure 1.
  • the crystalline Form KI of ibrutinib is characterized by a DSC thermogram having an endothermic peak at about 128 ⁇ 3 °C, preferably 128 ⁇ 2 °C, more preferably 128 ⁇ 1 °C.
  • the crystalline Form KI of ibrutinib is characterized by a DSC thermogram having an endothermic peak at about 128 ⁇ 3 °C, preferably 128 ⁇ 2 °C, more preferably 128 ⁇ 1 °C, and onset temperature in the range from 113 °C to 119 °C.
  • the crystalline Form KI of ibrutinib is characterized by a DSC thermogram substantially the same as shown in Figure 1.
  • the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3 ⁇ 0.I°, 8.8 ⁇ 0.1°, 11.7 ⁇ 0.1°, 13.1 ⁇ 0.1°, 14.9 ⁇ 0.1°, 16.8 ⁇ 0.1° 2Theta, and a DSC thermogram having an endothermic peak at about 128 ⁇ 3 °C.
  • XRPD X-ray powder diffraction
  • the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3 ⁇ 0.I°, 8.8 ⁇ 0.1°, 11.2 ⁇ 0.1°, 11.7 ⁇ 0.1°, 13.1 ⁇ 0.1°, 14.9 ⁇ 0.1°, 15.2 ⁇ 0.1°, 16.8 ⁇ 0.1°, 18.5 ⁇ 0.1° 2Theta, and a DSC thermogram having an endothermic peak at about 128 ⁇ 3 °C.
  • XRPD X-ray powder diffraction
  • the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3 ⁇ 0.1°, 8.8 ⁇ 0.1°, 11.2 ⁇ 0.1°, 11.7 ⁇ 0.1°, 13.1 ⁇ 0.1°, 14.9 ⁇ 0.1°, 15.2 ⁇ 0.1°, 16.8 ⁇ 0.1°, 18.5 ⁇ 0.1°, 20.1 ⁇ 0.1°, 21.7 ⁇ 0.1°, 23.8 ⁇ 0.1° 2Theta, and a DSC thermogram having an endothermic peak at about 128 ⁇ 3 °C.
  • XRPD X-ray powder diffraction
  • particles of the crystalline Form KI of ibrutinib are mainly in the form plate-like primary particles, that optionally form agglomerates.
  • particles of the crystalline Form KI of ibrutinib are mainly in the form of spherical agglomerates composed of plate-like primary particles, fused from the center outwards.
  • crystalline Form A, Form B and Form DI were obtained from a mixture methanol and water already, we have surprisingly found that from a mixture of alcohol, preferably methanol, and water an additional crystalline form of ibrutinib can be obtained, namely the above described crystalline Form KI.
  • ibrutinib Form KI is obtained by crystallization from a mixture of methanol and water having an excess of water and by controlling a temperature range.
  • the starting material in all processes described below can be obtained by any suitable process for preparing ibrutinib, including processes known in the art.
  • the ibrutinib starting material is obtained as described in WO 2016/115356.
  • Another aspect of the present invention is a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more
  • a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from
  • step a) 10 to 30 ml of alcohol is used per gram of ibrutinib, preferably 10 to 20 ml of alcohol is used per gram of ibrutinib, more preferably 10 to 15 ml of alcohol is used per gram of ibrutinib.
  • ibrutinib is dissolved at temperature from 45 °C to 70 °C, preferably at temperature from 50 °C to 60 °C, more preferably at temperature from 50 °C to 55 °C.
  • a volume ratio between alcohol and water is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1: 1 to 1:2, most preferably 1: 1.5.
  • a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from
  • the process for preparing the crystalline Form KI of ibrutinib is even more efficient if the seed crystals of crystalline Form KI of ibrutinib are used in the process.
  • the seed crystals are typically added in an amount of 0.1 wt% to 10 wt%, preferably in an amount of 0.5 wt% to 7.0 wt%, most preferably 1 .0 wt.% 5.0 wt%, on the basis of the total amount of ibrutinib dissolved in step a).
  • the seed crystals of crystalline Form KI of ibrutinib may be obtained by the processes for preparing the crystalline Form KI of ibrutinib as described in any of the above embodiments.
  • step c) comprises the following sub-steps: cl) adding the first portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; c2) optionally, adjusting a temperature of the solution obtained in step cl) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c3) adding seed crystals of the crystalline Form KI of ibrutinib; and c4) adding the second portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C.
  • the first portion of water added in step cl) represents from 10 to 30%, preferably from 10 to 20%, of the amount of water added in step cl) and step c4) together.
  • a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; cl) adding the first portion of water having a temperature from 5 to 35 °C, preferably from 5 to 25 °C, more preferably from 10 to 25 °C; c2) optionally, adjusting a temperature of the solution obtained in step cl) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 35
  • a ratio between alcohol and water added in step cl) and in step c4) together is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1: 1 to 1:2, most preferably 1: 1.5.
  • a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; cl) adding the first portion of water having a temperature from 5 to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; c2) optionally, adjusting a temperature of the solution obtained in step cl) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, most preferably from 20 °C to 35 °C; c3) adding seed
  • a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; cl) adding the first portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; c2) adjusting a temperature of the solution obtained in step cl) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, most preferably from 20 °C to 35 °C; c3) adding seed
  • a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 25 °C to 35 °C; cl) adding the first portion of water having a temperature from 10 °C to 25 °C; c2) adjusting a temperature of the solution obtained in step cl) to a temperature from 20 °C to 35 °C; c3) adding seed crystals of crystalline Form KI of ibrutinib; c4) adding the second portion of water having a temperature from 10 °C to 25 °C; d) adjusting a temperature of the solution obtained in step c4) to a temperature from 20 °C to 35 °C; g) stirring; and h) isolating crystalline material; wherein a ratio between
  • a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 25 °C to 35 °C; cl) adding the first portion of water having a temperature from 10 °C to 25 °C; c2) adjusting a temperature of the solution obtained in step cl) to a temperature from 20 °C to 35 °C; c3) adding seed crystals of crystalline Form KI of ibrutinib; c4) adding the second portion of water having a temperature from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c4) to a temperature from 20 °C to 35 °C; g) stirring; and h) isolating crystalline material; wherein
  • step j) suspension is stirred preferably for 1 to 24 hours, more preferably 2 to 12 hours, most preferably 3 to 8 hours.
  • the process for preparing the crystalline Form KI of ibrutinib comprises the following additional steps: i) suspending crystalline material obtained in step h) in methanol : water mixture, wherein a volume ratio between alcohol and water is from 9: 1 to 7:3, preferably 6: 1 to 3: 1, more preferably 4: 1; j) stirring; and k) isolating crystalline material.
  • Isolation in step h) or step k) may be performed by any method known in the art, such as fdtration, centrifugation, or evaporation of solvent.
  • the isolated crystals may optionally be dried, e.g. under reduced pressure, typically at a temperature between 20 °C and 30 °C or the crystals may directly be used in further processes.
  • Another aspect of the present invention is a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) optionally, adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) optionally, adding the second portion of water having a
  • a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; f) cooling a suspension to a temperature from 0 °C to 15 °
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) optionally, adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) optionally, adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C
  • step a) 5 to 30 ml of solvent mixture is used per gram of ibrutinib, preferably 5 to 20 ml of solvent mixture is used per gram of ibrutinib, more preferably 5 to 10 ml of solvent mixture is used per gram of ibrutinib.
  • a volume ratio between alcohol and water is from 10: 1 to 1: 1, preferably from 8: 1 to 2: 1, more preferably from 6: 1 to 4: 1, most preferably 5: 1.
  • ibrutinib is dissolved at temperature from 45 °C to 70 °C, preferably at temperature from 50 °C to 60 °C, more preferably at temperature from 50 °C to 55 °C.
  • a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of methanol and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40
  • the process for preparing the crystalline Form KI of ibrutinib is even more efficient if the seed crystals of crystalline Form KI of ibrutinib are used in the process.
  • the seed crystals are typically added in an amount of 0.1 wt% to 10 wt%, preferably in an amount of 0.5 wt% to 7.0 wt%, most preferably 1 .0 wt.% 5.0 wt%, on the basis of the total amount of ibrutinib dissolved in step a).
  • the seed crystals of crystalline Form KI of ibrutinib may be obtained by the processes for preparing the crystalline Form KI of ibrutinib as described in any of the above embodiments.
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °
  • step a) 5 to 30 ml of solvent mixture is used per gram of ibrutinib, preferably 5 to 20 ml of solvent mixture is used per gram of ibrutinib, more preferably 5 to 10 ml of solvent mixture is used per gram of ibrutinib.
  • a volume ratio between alcohol and water is from 10: 1 to 1: 1, preferably from 8: 1 to 2: 1, more preferably from 6: 1 to 4: 1, most preferably 5: 1.
  • ibrutinib is dissolved at temperature from 45 °C to 70 °C, preferably at temperature from 50 °C to 60 °C, more preferably at temperature from 50 °C to 55 °C.
  • a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C;
  • a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C;
  • the process for preparing the crystalline Form KI of ibrutinib comprises the following additional steps: i) suspending crystalline material obtained in step h) in methanol : water mixture, wherein a volume ratio between alcohol and water is from 9: 1 to 7:3, preferably 6: 1 to 3: 1, more preferably 4: 1; j) stirring; and k) isolating crystalline material.
  • step d) suspension is stirred preferably for 1 to 24 hours, more preferably 2 to 12 hours, most preferably 3 to 8 hours, before the second portion of water is added in step e).
  • step j) suspension is stirred preferably for 1 to 24 hours, more preferably 2 to 12 hours, most preferably 3 to 8 hours.
  • Isolation in step h) or step k) may be performed by any method known in the art, such as filtration, centrifugation, or evaporation of solvent.
  • the isolated crystals may optionally be dried, e.g. under reduced pressure, typically at a temperature between 20 °C and 30 °C or the crystals may directly be used in further processes.
  • compositions comprising the crystalline Form KI of ibrutinib and at least one pharmaceutically acceptable excipient.
  • the pharmaceutical composition is an oral solid dosage form, such as, but not limited to, capsules, tablet, lozenge, pastille, pill, dragee, powder, granules, pellets.
  • Pharmaceutical compositions may be manufactured by a conventional methods, such as, but not limited to, mixing, dry granulation, wet granulation, encapsulation, or compression.
  • the pharmaceutically acceptable excipient is selected, but not limited to, from the group consisting of diluents, fdlers, binders, disintegrants, glidants, lubricants, colorants, surfactants.
  • excipients are microcrystalline cellulose, lactose, mannitol, sorbitol, calcium carbonate, silicified microcrystalline cellulose, pregelatinized starch, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, hydroxypropylethycellulose, croscarmel- lose, croscarmellose sodium, sodium starch glycolate, povidone, crospovidone, sodium lauryl sulfate, polyvinyl alcohol, macrogol, magnesium stearate, talc, colloidal anhydrous silica, ferric oxides, titanium dioxide.
  • the crystalline Form KI of ibrutinib is administrated in the amount from 300 mg/day to 1000 mg/day, preferably from 420 mg/day to 840 mg/day, more preferably from 420 mg/day to 840 mg/day 560 mg/day, most preferably in the amount 420 mg/day.
  • Another aspect of the present invention is use of the crystalline Form KI of ibrutinib or a pharmaceutical composition comprising the crystalline Form KI of ibrutinib for inhibiting Bruton's tyrosine kinase activity or for the treatment of a disease, disorder, or condition, which would benefit from inhibition of Bruton's tyrosine kinase activity.
  • the crystalline Form KI of ibrutinib or a pharmaceutical composition comprising the crystalline Form KI of ibrutinib are used for the treatment of cancer, autoimmune diseases or conditions, heteroimmune diseases or conditions, and inflammatory diseases or conditions.
  • the cancer is a B cell malignancy selected from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B Cell lymphoma (DLBCL), and multiple myeloma.
  • CLL chronic lymphocytic leukemia
  • SLL small lymphocytic lymphoma
  • MCL mantle cell lymphoma
  • DLBCL diffuse large B Cell lymphoma
  • multiple myeloma multiple myeloma
  • the cancer is diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, nodal marginal zone B cell lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.
  • the autoimmune disease is inflammatory bowel disease, arthritis, lupus, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease Sjogren's syndrome, multiple sclerosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitisis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease, Goodpasture's syndrome, idiopathic throm- bocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, autoimmune
  • the inflammatory disease is asthma, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis, cystitis, dacry- oadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis,
  • DSC measurements were performed on DSC 1 Mettler Toledo. 3 mg of sample was weighted in 40 pL aluminum crucibles with perforated lid. Sample was heated with linear heating rate 10 K/min up to 190 °C in the flow of nitrogen, 40 mL/min.
  • Particle morphology images were collected by FEG Carl Zeiss ULTRA plus scanning electron microscope using Evemhart-Thomley secondary electron detector at 3. 1 mm working distance, 1 kV EHT and 30 pm aperture size.
  • IDR Intrinsic dissolution rate
  • Ibrutinib 50g was dissolved in methanol (750 m ) at 55 °C. Solution was filtered and cooled to 25 to 30 °C. During stirring cold water (1125 m ) at 15-20 °C was added in 2 hours. After addition, temperature was below 29 °C and crystallization occurred. Suspension was cooled to 5-10 °C and stirred for 4 hours. Material vas filtered and rinsed with chilled water. Wet material was suspended in methanol : water mixture (8V:2V) and stirred for 4 hours. Suspension was filtered and so obtained material was dried in vacuum dryer at 30 °C. Dried product (36 g) moisture content was 0.26% and content of residual methanol was below limit of detection.
  • Ibrutinib 50g was dissolved in methanol (500 mb) at 55 °C. Solution was filtered and cooled to 30-35 °C. During stirring water (150 mb) at 20°C and seeding crystals (1500 mg), obtained by the Example 1, were added into the mixture at temperature 33 °C. East lot of water (600 mb) at 20 °C was added in 2 hours. After addition temperature was below 30 °C. Suspension was cooled to 5-10 °C and stirred for 4 hours. Material was filtered and rinsed with chilled water. Wet material was suspended in methanol : water mixture (8V:2V) and stirred for 4 hours. Suspension was filtered and so obtained material was dried in vacuum dryer at 30 °C. Dried product (37 g) moisture content was 0.27% and content of residual methanol was below limit of detection.
  • Ibrutinib 35g was dissolved in methanol (350 mb) at 55 °C. Solution was filtered and cooled to 30-35 °C. During stirring water (70 mb) at 5-10°C and seeding crystals (350 mg) were added into the mixture at temperature 32 °C. East lot of water (455 mb) at 20 °C was added in 1 hour. After addition temperature was 30 °C. Suspension was cooled to 5-10 °C and stirred for 4 hours. Material was filtered and rinsed with chilled water and so obtained material was dried in vacuum dryer at 30 °C. Dried product (29.5 g grams) moisture content was 0.46% and content of residual methanol was below limit of detection.
  • Ibrutinib 50g was dissolved in mixture of methanol (500 mb) and water (100 mb) at 52 °C. Clear solution was filtered through 0.5 urn filter, cooled to 30 °C and seeding crystals of form KI (500 mg) were added. After seeding suspension was left to crystallize for 30 minutes followed by heating of suspension to 35 °C over 2 hours. After 35 °C was reached suspension was stirred for additional 2 hours. Preheated water at 33 °C (650 mb) was gradually added into the suspension over 1 hour. Suspension was stirred for 2 hour at 35 °C and material was filtered and dried in vacuum try dryer at 30 °C under vacuum of 100 mbar and nitrogen flow. Dried product (44.3 g) moisture content was 0.31% and content of residual methanol was below limit of detection.

Abstract

The present invention relates to crystalline form of ibrutinib, designated as Form K1, and processes for its preparation.

Description

Crystalline form of ibrutinib
Priority
[0001] Priority is claimed of Slovenian patent application no. P-2022 00096 that was filed on June 17, 2022.
Technical Field
[0002] The present invention relates to crystalline form of ibrutinib, designated as Form KI, and processes for its preparation.
Background of the invention
[0003] Ibrutinib is an inhibitor of Bruton's tyrosine kinase (BTK). The chemically name of ibrutinib is l-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-lH-pyrazolo[3,4-d]pyrimidin-l-yl]piperidin-l-yl]prop- 2-en-l-one and it has the following formula:
Figure imgf000002_0001
[0004] Ibrutinib was first disclosed in WO 2008/039218.
[0005] Different crystalline forms of ibrutinib are known already.
[0006] WO 2013/184572 discloses amorphous form, crystalline forms and solvates of ibrutinib, designated as Form A, Form B, Form C, Form D, Form E and Form F.
[0007] CN 103694241 discloses crystalline form A of ibrutinib.
[0008] CN 103923084 discloses anhydrous forms, hydrates and solvates of ibrutinib, designated as form II, form III, form IV, form V, form VI, form VII and form VIII.
[0009] WO 2015/081180 discloses a crystalline form of ibrutinib, designated as Form I.
[0010] WO 2015/145415 discloses anhydrous forms, hydrates and solvates of ibrutinib, designated as Form III, Form IV, Form V, Form VI, Form VII, Form VIII and Form IX. [0011] WO 2016/025720 discloses crystalline forms and solvates of ibrutinib designated as Form G, Form J and Form K.
[0012] WO 2016/079216 and WO 2016/160598 disclose solvates of ibrutinib.
[0013] WO 2016/139588 discloses crystalline forms and solvates of ibrutinib designated as Form DI, Form Dla, Form D2, Form D2a, Form D3, Form D4, Form D5, Form D6, Form D7, Form D8, Form D9, Form D10, Form Dl l, Form D12 and Form D13.
[0014] WO 2017/029586 discloses crystalline forms of ibrutinib, designated as Form SI, Form S2, Form S3, Form S4, and an amorphous form, designated as Form Al.
[0015] CN 105646484 discloses a crystalline form B of ibrutinib.
[0016] CN 105646498 discloses a crystalline form F of ibrutinib.
[0017] WO 2016/160604 discloses ibrutinib co-crystals with organic acids.
[0018] Known crystalline forms of ibrutinib show different properties regarding dissolution, stability, processing, etc. However, there is still a need for a new crystalline form of ibrutinib and a process for preparing it. Particularly, there is a need for a new crystalline form of ibrutinib having a good balance between dissolution properties and stability properties. Furthermore, there is a need for a new crystalline form of ibrutinib having good handling and/or processing properties.
Summary of the invention
[0019] The present invention is described by the following items:
(1) A crystalline Form KI of ibrutinib.
(2) The crystalline Form KI of ibrutinib according to item (1) characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3±0.1°, 8.8±0.1°, 11.7±0.1°, 13.1±0.1°, 14.9±0.1°, and 16.8±0,l° 2Theta.
(3) The crystalline Form KI of ibrutinib according to item (1) or item (2) characterized by X- ray powder diffraction (XRPD) pattern having additional characteristic peaks at 11.2±0.1°, 15.2±0.1°, 18.5±0.1° 2Theta.
(4) The crystalline Form KI of ibrutinib according to any one of items (1) to (3) characterized by X-ray powder diffraction (XRPD) pattern having additional characteristic peaks at 20.1±0.1°, 21.7±0.1° and 23.8±0.1° 2Theta.
(5) The crystalline Form KI of ibrutinib according to any of items (1) to (4) characterized by X- ray powder diffraction (XRPD) pattern having additional characteristic peaks at 5.7±0.1°, 6.6±0.1°, 8.4±0.1°, 10.8±0.1°, 11.9±0.1°, 13.7±0.1°, 15.9±0.1°, 16.6±0.1°, 17.7±0.1°, 19.0±0.1°, 20.9±0.1°, 22.0±0.1°, 23.0±0.1°, 24.5±0.1°, 25.7±0.1°, 26.8±0.1°, 28.1±0.1°, 29.7±0.1°, 30.6±0.1°, 31.4±0.1°, 32.0±0.1° 2Theta.
(6) The crystalline Form KI of ibrutinib according to any one of items (1) to (5) characterized by a DSC thermogram having an endothermic peak at about 128±3 °C.
(7) The crystalline Form KI of ibrutinib according to any one of items (1) to (6) characterized by mainly spherical agglomerates composed of plate-like primary particles, fused from the center outwards.
(8) A process for preparing the crystalline Form KI of ibrutinib according to any one of items (1) to (7) comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 20 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) optionally, adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
(9) The process for preparing the crystalline Form KI of ibrutinib according to item (8) comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 20 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
(10) The process for preparing the crystalline Form KI of ibrutinib according to item (8) or item (9) comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 20 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C, preferably from 25; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; f) cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
(11) The process according to any one of items (8) to (10), wherein in step a) 10 to 30 ml of alcohol is used per gram of ibrutinib, preferably 10 to 20 ml of alcohol is used per gram of ibrutinib, more preferably 10 to 15 ml of alcohol is used per gram of ibrutinib.
(12) The process according to any one of items (8) to (11), wherein in step c) a ratio between alcohol and water is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1: 1 to 1:2, most preferably 1: 1.5.
(13) The process for preparing the crystalline Form KI of ibrutinib according to item (8) or items (9) to (12), wherein a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5. (14) The process according to any one of items (8) to (13), wherein in step c) seed crystals of crystalline Form KI ofibrutinib are added.
(15) The process according to any one of items (8) to (14) comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 20 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; cl) adding the first portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; c2) optionally, adjusting a temperature of the solution obtained in step cl) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c3) adding seed crystals of crystalline Form KI of ibrutinib; c4) adding the second portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c4) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
(16) The process according to item (15), wherein a ratio between alcohol and water in the mixture obtained in step c4) is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1 : 1 to 1:2, most preferably 1: 1.5.
(17) A process for preparing the crystalline Form KI of ibrutinib according to any one of items (1) to (7) comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30
Figure imgf000006_0001
d) optionally, adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 to 45 °C, preferably from 30 to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
(18) The process according to item (17), comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) optionally, adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; g) optionally, stirring; and h) isolating crystalline material.
(19) The process according to item (17) or item (18), comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
(20) The process according to any one of items (17) to (19), comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; g) stirring; and h) isolating crystalline material.
(21) The process according to any one of items (17) to (20), wherein in step a) 5 to 30 ml of solvent mixture is used per gram of ibrutinib, preferably 5 to 20 ml of solvent mixture is used per gram of ibrutinib, more preferably 5 to 10 ml of solvent mixture is used per gram of ibrutinib.
(22) The process according to any one of items (17) to (21), wherein in step a) a volume ratio between alcohol and water is from 10: 1 to 1: 1, preferably from 8: 1 to 2: 1, more preferably from 6: 1 to 4: 1, most preferably 5: 1.
(23) The process according to any one of items (8) to (22), wherein in step a) ibrutinib is dissolved at temperature from 45 °C to 70 °C, preferably at temperature from 50 °C to 60 °C, more preferably at temperature from 50 °C to 55 °C.
(24) The process according to any one of items (17) to (23), wherein a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1 : 1 to 1 : 1.5.
(25) The process according to any one of items (8) to (24), comprising the following additional steps: i) suspending crystalline material obtained in step h) in methanol : water mixture, wherein a volume ratio between alcohol and water is from 9: 1 to 7:3, preferably 6: 1 to 3: 1, more preferably 4: 1; j) stirring; and k) isolating crystalline material.
Brief description of the Figures
[0020] Figure 1 illustrates an X-ray powder diffraction (XRPD) pattern of a crystalline Form KI of ibrutinib.
[0021] Figure 2 illustrates a Differential Scanning Calorimetry (DSC) thermogram of a crystalline Form KI of ibrutinib.
[0022] Figure 3 illustrates SEM of a crystalline Form KI of ibrutinib.
Detailed description of the invention
[0023] As well-known so called 'kinetic' polymorphs shows better dissolution rate that is advantageous during formulation technology and afford several simplification in technology and composition to prepare efficient final dosage formulation. On contrary, it is also known that so called kinetic polymorphs are difficult to produce in polymorphic pure form in robust manner, they often exhibit weak crystallographic and chemical stability and special solvent systems and technologies are required. That is drawback that need to be overcome to make kinetic polymorph useful and profitable for production on industrial scale.
[0024] Surprisingly, new crystalline form of ibrutinib Form KI shows improved dissolution rates compared to thermodynamically more stable forms, like form A, but at the same time it shows good chemical stability and polymorphic stability what is not the case for other kinetic forms of ibrutinib with low crystallinity or even amorphous.
[0025] Regarding processes used for kinetic polymorphs it is well known that they are accompanied with unwanted particle morphology that often lead to slow filtration rates, slow drying process, increased level of residual solvents and water, all that can affect quality, purity, stability and profitability of production of kinetic polymorph.
[0026] Crystalline Form KI of ibrutinib has good filterability that afford good washing of filtered wet cake, good purity and efficient drying resulting in residual organic solvents below limit of detection and very low moisture content. Additionally, crystalline Form KI of ibrutinib shows favorable morphology in view of good handling, particularly good flowability.
[0027] First aspect of the present invention is a crystalline Form KI of ibrutinib. [0028] In one embodiment, the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3±0.1°, 8.8±0.1°, 11.7±0.1°, 13.1±0.1°, 14.9±0.1°, and 16.8±0.1° 2Theta.
[0029] In another embodiment, the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3±0.1°, 8.8±0.1°, 11.2±0.1°, 11.7±0.1°, 13.1±0.1°, 14.9±0.1°, I5.2±0.I°, 16.8±0.1°, and 18.5±0.1° 2Theta.
[0030] In another embodiment, the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3±0.1°, 8.8±0.1°, 11.2±0.1°, 11.7±0.1°, 13.1±0.1°, 14.9±0.1°, I5.2±0,I°, 16.8±0.1°, 18.5±0.1°, 20.1±0.1°, 21.7±0.1°, and 23.8±0.1° 2Theta.
[0031] In another embodiment, the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3±0.1°, 5.7±0.1°, 6.6±0.1°, 8.4±0.1°, 8.8±0.1°, 10.8±0.1°, 11.2±0.1°, 11.7±0.1°, 11.9±0.1°, 13.1±0.1°, 13.7±0.1°, 14.9±0.1°, 15.2±0.1°, 15.9±0.I°, 16.6±0.1°, 16.8±0.1°, 17.7±0.1°, 18.5±0.1°, 19.0±0.1°, 20.1±0.1°, 20.9±0.1°, 21.7±0.1°, 22.0±0.1°, 23.0±0.1°, 23.8±0.1°, 24.5±0.1°, 25.7±0.1°, 26.8±0.1°, 28.1±0.1°, 29.7±0.1°, 30.6±0.1°, 31.4±0.1°, and 32.0 ± 0.1° 2Theta.
[0032] In another embodiment, the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern substantially the same as shown in Figure 1.
[0033] In another embodiment, the crystalline Form KI of ibrutinib is characterized by a DSC thermogram having an endothermic peak at about 128±3 °C, preferably 128±2 °C, more preferably 128±1 °C.
[0034] In another embodiment, the crystalline Form KI of ibrutinib is characterized by a DSC thermogram having an endothermic peak at about 128±3 °C, preferably 128±2 °C, more preferably 128±1 °C, and onset temperature in the range from 113 °C to 119 °C.
[0035] In another embodiment, the crystalline Form KI of ibrutinib is characterized by a DSC thermogram substantially the same as shown in Figure 1.
[0036] In another embodiment, the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3±0.I°, 8.8±0.1°, 11.7±0.1°, 13.1±0.1°, 14.9±0.1°, 16.8±0.1° 2Theta, and a DSC thermogram having an endothermic peak at about 128±3 °C.
[0037] In another embodiment, the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3±0.I°, 8.8±0.1°, 11.2±0.1°, 11.7±0.1°, 13.1±0.1°, 14.9±0.1°, 15.2±0.1°, 16.8±0.1°, 18.5±0.1° 2Theta, and a DSC thermogram having an endothermic peak at about 128±3 °C. [0038] In another embodiment, the crystalline Form KI of ibrutinib is characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3±0.1°, 8.8±0.1°, 11.2±0.1°, 11.7±0.1°, 13.1±0.1°, 14.9±0.1°, 15.2±0.1°, 16.8±0.1°, 18.5±0.1°, 20.1±0.1°, 21.7±0.1°, 23.8±0.1° 2Theta, and a DSC thermogram having an endothermic peak at about 128±3 °C.
[0039] In another embodiment, particles of the crystalline Form KI of ibrutinib are mainly in the form plate-like primary particles, that optionally form agglomerates.
[0040] In another embodiment, particles of the crystalline Form KI of ibrutinib are mainly in the form of spherical agglomerates composed of plate-like primary particles, fused from the center outwards.
[0041] Although crystalline Form A, Form B and Form DI were obtained from a mixture methanol and water already, we have surprisingly found that from a mixture of alcohol, preferably methanol, and water an additional crystalline form of ibrutinib can be obtained, namely the above described crystalline Form KI. We have found that ibrutinib Form KI is obtained by crystallization from a mixture of methanol and water having an excess of water and by controlling a temperature range.
[0042] The starting material in all processes described below can be obtained by any suitable process for preparing ibrutinib, including processes known in the art. For example, the ibrutinib starting material is obtained as described in WO 2016/115356.
[0043] Another aspect of the present invention is a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) optionally, adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
[0044] In one embodiment, a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; f) cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
[0045] In one embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
[0046] In one embodiment, in step a) 10 to 30 ml of alcohol is used per gram of ibrutinib, preferably 10 to 20 ml of alcohol is used per gram of ibrutinib, more preferably 10 to 15 ml of alcohol is used per gram of ibrutinib.
[0047] In one embodiment, in step a) ibrutinib is dissolved at temperature from 45 °C to 70 °C, preferably at temperature from 50 °C to 60 °C, more preferably at temperature from 50 °C to 55 °C.
[0048] In one embodiment, in step c) a volume ratio between alcohol and water is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1: 1 to 1:2, most preferably 1: 1.5. [0049] In one embodiment, a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
[0050] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) stirring; and h) isolating crystalline material; wherein, in step c) a volume ratio between alcohol and water is from 2: 1 to 1 :4, preferably from 1.5: 1 to 1:3, more preferably from 1 : 1 to 1:2, most preferably 1 : 1.5, and wherein, a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
[0051] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; f) cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) stirring; and h) isolating crystalline material; wherein, in step c) a volume ratio between methanol and water is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1: 1 to 1:2, most preferably 1: 1.5, and wherein, a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
[0052] The process for preparing the crystalline Form KI of ibrutinib is even more efficient if the seed crystals of crystalline Form KI of ibrutinib are used in the process.
[0053] The seed crystals are typically added in an amount of 0.1 wt% to 10 wt%, preferably in an amount of 0.5 wt% to 7.0 wt%, most preferably 1 .0 wt.% 5.0 wt%, on the basis of the total amount of ibrutinib dissolved in step a).
[0054] The seed crystals of crystalline Form KI of ibrutinib may be obtained by the processes for preparing the crystalline Form KI of ibrutinib as described in any of the above embodiments.
[0055] In one preferred embodiment, step c) comprises the following sub-steps: cl) adding the first portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; c2) optionally, adjusting a temperature of the solution obtained in step cl) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c3) adding seed crystals of the crystalline Form KI of ibrutinib; and c4) adding the second portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C.
[0056] In one embodiment, the first portion of water added in step cl) represents from 10 to 30%, preferably from 10 to 20%, of the amount of water added in step cl) and step c4) together.
[0057] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; cl) adding the first portion of water having a temperature from 5 to 35 °C, preferably from 5 to 25 °C, more preferably from 10 to 25 °C; c2) optionally, adjusting a temperature of the solution obtained in step cl) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c3) adding seed crystals of crystalline Form KI of ibrutinib; c4) adding the second portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c4) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, most preferably from 20 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
[0058] In one embodiment, a ratio between alcohol and water added in step cl) and in step c4) together is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1: 1 to 1:2, most preferably 1: 1.5.
[0059] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; cl) adding the first portion of water having a temperature from 5 to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; c2) optionally, adjusting a temperature of the solution obtained in step cl) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, most preferably from 20 °C to 35 °C; c3) adding seed crystals of crystalline Form KI of ibrutinib; c4) adding the second portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c4) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, most preferably from 20 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material; wherein a ratio between alcohol and water in the mixture obtained in step c4) is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1: 1 to 1:2, most preferably 1: 1.5.
[0060] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 20 °C to 50 °C, preferably from 25 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; cl) adding the first portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; c2) adjusting a temperature of the solution obtained in step cl) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, most preferably from 20 °C to 35 °C; c3) adding seed crystals of crystalline Form KI of ibrutinib; c4) adding the second portion of water having a temperature from 5 °C to 35 °C, preferably from 5 °C to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c4) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, most preferably from 20 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material; wherein a ratio between alcohol and water in the mixture obtained in step c4) is from 1: 1 to 1:2, preferably 1: 1.5.
[0061] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 25 °C to 35 °C; cl) adding the first portion of water having a temperature from 10 °C to 25 °C; c2) adjusting a temperature of the solution obtained in step cl) to a temperature from 20 °C to 35 °C; c3) adding seed crystals of crystalline Form KI of ibrutinib; c4) adding the second portion of water having a temperature from 10 °C to 25 °C; d) adjusting a temperature of the solution obtained in step c4) to a temperature from 20 °C to 35 °C; g) stirring; and h) isolating crystalline material; wherein a ratio between alcohol and water in the mixture obtained in step c4) is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1: 1 to 1:2, most preferably 1: 1.5.
[0062] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature from 25 °C to 35 °C; cl) adding the first portion of water having a temperature from 10 °C to 25 °C; c2) adjusting a temperature of the solution obtained in step cl) to a temperature from 20 °C to 35 °C; c3) adding seed crystals of crystalline Form KI of ibrutinib; c4) adding the second portion of water having a temperature from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c4) to a temperature from 20 °C to 35 °C; g) stirring; and h) isolating crystalline material; wherein a ratio between alcohol and water in the mixture obtained in step c4) is from 1: 1 to 1:2, preferably 1: 1.5.
[0063] In preferred embodiments, in step j) suspension is stirred preferably for 1 to 24 hours, more preferably 2 to 12 hours, most preferably 3 to 8 hours.
[0064] In alternative embodiment, the process for preparing the crystalline Form KI of ibrutinib according to any one of embodiments above comprises the following additional steps: i) suspending crystalline material obtained in step h) in methanol : water mixture, wherein a volume ratio between alcohol and water is from 9: 1 to 7:3, preferably 6: 1 to 3: 1, more preferably 4: 1; j) stirring; and k) isolating crystalline material.
[0065] Isolation in step h) or step k) may be performed by any method known in the art, such as fdtration, centrifugation, or evaporation of solvent. Moreover, the isolated crystals may optionally be dried, e.g. under reduced pressure, typically at a temperature between 20 °C and 30 °C or the crystals may directly be used in further processes.
[0066] Another aspect of the present invention is a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) optionally, adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) optionally, adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material. [0067] According to this aspect water mixed with alcohol in step a) is considered as the first portion of water.
[0068] In one embodiment, a process for preparing the crystalline Form KI of ibrutinib comprises the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; f) cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
[0069] In one embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) optionally, adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
[0070] In one embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) optionally, adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; g) optionally, stirring; and h) isolating crystalline material.
[0071] In one embodiment, in step a) 5 to 30 ml of solvent mixture is used per gram of ibrutinib, preferably 5 to 20 ml of solvent mixture is used per gram of ibrutinib, more preferably 5 to 10 ml of solvent mixture is used per gram of ibrutinib.
[0072] In one embodiment, in step a) a volume ratio between alcohol and water is from 10: 1 to 1: 1, preferably from 8: 1 to 2: 1, more preferably from 6: 1 to 4: 1, most preferably 5: 1.
[0073] In one embodiment, in step a) ibrutinib is dissolved at temperature from 45 °C to 70 °C, preferably at temperature from 50 °C to 60 °C, more preferably at temperature from 50 °C to 55 °C.
[0074] In one embodiment, a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
[0075] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) stirring; and h) isolating crystalline material; wherein, in step a) a volume ratio between alcohol and water is from 10: 1 to 1: 1, preferably from 8: 1 to 2: 1, more preferably from 6: 1 to 4: 1, most preferably 5: 1, and wherein, a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5. [0076] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of methanol and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) adjusting a temperature of the solution obtained in step b) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; g) stirring; and h) isolating crystalline material; wherein, in step a) a volume ratio between alcohol and water is from 10: 1 to 1: 1, preferably from 8: 1 to 2: 1, more preferably from 6: 1 to 4: 1, most preferably 5: 1, and wherein, a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
The process for preparing the crystalline Form KI of ibrutinib is even more efficient if the seed crystals of crystalline Form KI of ibrutinib are used in the process.
[0077] The seed crystals are typically added in an amount of 0.1 wt% to 10 wt%, preferably in an amount of 0.5 wt% to 7.0 wt%, most preferably 1 .0 wt.% 5.0 wt%, on the basis of the total amount of ibrutinib dissolved in step a).
[0078] The seed crystals of crystalline Form KI of ibrutinib may be obtained by the processes for preparing the crystalline Form KI of ibrutinib as described in any of the above embodiments.
[0079] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) optionally, adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
[0080] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material.
[0081] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; g) stirring; and h) isolating crystalline material. [0082] In one embodiment, in step a) 5 to 30 ml of solvent mixture is used per gram of ibrutinib, preferably 5 to 20 ml of solvent mixture is used per gram of ibrutinib, more preferably 5 to 10 ml of solvent mixture is used per gram of ibrutinib.
[0083] In one embodiment, in step a) a volume ratio between alcohol and water is from 10: 1 to 1: 1, preferably from 8: 1 to 2: 1, more preferably from 6: 1 to 4: 1, most preferably 5: 1.
[0084] In one embodiment, in step a) ibrutinib is dissolved at temperature from 45 °C to 70 °C, preferably at temperature from 50 °C to 60 °C, more preferably at temperature from 50 °C to 55 °C.
[0085] In one embodiment, a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
[0086] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material; wherein, in step a) a volume ratio between alcohol and water is from 10: 1 to 1: 1, preferably from 8: 1 to 2: 1, more preferably from 6: 1 to 4: 1, most preferably 5: 1, and wherein, a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
[0087] In one preferred embodiment, a process for preparing the crystalline Form KI of ibrutinib comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably from 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding seed crystals of crystalline Form KI of ibrutinib; d) adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; g) stirring; and h) isolating crystalline material; wherein, in step a) a volume ratio between alcohol and water is from 10: 1 to 1: 1, preferably from 8: 1 to 2: 1, more preferably from 6: 1 to 4: 1, most preferably 5: 1, and wherein, a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5.
[0088] In alternative embodiment, the process for preparing the crystalline Form KI of ibrutinib according to any one of embodiments above comprises the following additional steps: i) suspending crystalline material obtained in step h) in methanol : water mixture, wherein a volume ratio between alcohol and water is from 9: 1 to 7:3, preferably 6: 1 to 3: 1, more preferably 4: 1; j) stirring; and k) isolating crystalline material.
[0089] In some preferred embodiments, after step d) suspension is stirred preferably for 1 to 24 hours, more preferably 2 to 12 hours, most preferably 3 to 8 hours, before the second portion of water is added in step e).
[0090] In preferred embodiments, in step j) suspension is stirred preferably for 1 to 24 hours, more preferably 2 to 12 hours, most preferably 3 to 8 hours.
[0091] Isolation in step h) or step k) may be performed by any method known in the art, such as filtration, centrifugation, or evaporation of solvent. Moreover, the isolated crystals may optionally be dried, e.g. under reduced pressure, typically at a temperature between 20 °C and 30 °C or the crystals may directly be used in further processes.
[0092] Another aspect of the present invention is a pharmaceutical composition comprising the crystalline Form KI of ibrutinib and at least one pharmaceutically acceptable excipient. Preferably, the pharmaceutical composition is an oral solid dosage form, such as, but not limited to, capsules, tablet, lozenge, pastille, pill, dragee, powder, granules, pellets. Pharmaceutical compositions may be manufactured by a conventional methods, such as, but not limited to, mixing, dry granulation, wet granulation, encapsulation, or compression. [0093] In one embodiment, the pharmaceutically acceptable excipient is selected, but not limited to, from the group consisting of diluents, fdlers, binders, disintegrants, glidants, lubricants, colorants, surfactants. Examples of suitable excipients are microcrystalline cellulose, lactose, mannitol, sorbitol, calcium carbonate, silicified microcrystalline cellulose, pregelatinized starch, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, hydroxypropylethycellulose, croscarmel- lose, croscarmellose sodium, sodium starch glycolate, povidone, crospovidone, sodium lauryl sulfate, polyvinyl alcohol, macrogol, magnesium stearate, talc, colloidal anhydrous silica, ferric oxides, titanium dioxide.
[0094] In one embodiment, the crystalline Form KI of ibrutinib is administrated in the amount from 300 mg/day to 1000 mg/day, preferably from 420 mg/day to 840 mg/day, more preferably from 420 mg/day to 840 mg/day 560 mg/day, most preferably in the amount 420 mg/day.
[0095] Another aspect of the present invention is use of the crystalline Form KI of ibrutinib or a pharmaceutical composition comprising the crystalline Form KI of ibrutinib for inhibiting Bruton's tyrosine kinase activity or for the treatment of a disease, disorder, or condition, which would benefit from inhibition of Bruton's tyrosine kinase activity.
[0096] In one embodiment, the crystalline Form KI of ibrutinib or a pharmaceutical composition comprising the crystalline Form KI of ibrutinib are used for the treatment of cancer, autoimmune diseases or conditions, heteroimmune diseases or conditions, and inflammatory diseases or conditions.
[0097] In one embodiment, the cancer is a B cell malignancy selected from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B Cell lymphoma (DLBCL), and multiple myeloma.
[0098] In one embodiment, the cancer is diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic lymphoma, chronic lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, nodal marginal zone B cell lymphoma, plasma cell myeloma, plasmacytoma, extranodal marginal zone B cell lymphoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.
[0099] In one embodiment, the autoimmune disease is inflammatory bowel disease, arthritis, lupus, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, Still's disease, juvenile arthritis, diabetes, myasthenia gravis, Hashimoto's thyroiditis, Ord's thyroiditis, Graves' disease Sjogren's syndrome, multiple sclerosis, Guillain-Barre syndrome, acute disseminated encephalomyelitis, Addison's disease, opsoclonus-myoclonus syndrome, ankylosing spondylitisis, antiphospholipid antibody syndrome, aplastic anemia, autoimmune hepatitis, coeliac disease, Goodpasture's syndrome, idiopathic throm- bocytopenic purpura, optic neuritis, scleroderma, primary biliary cirrhosis, Reiter's syndrome, Takayasu's arteritis, temporal arteritis, autoimmune hemolytic anemia, warm autoimmune hemolytic anemia, cold hemolytic anemia, Wegener's granulomatosis, psoriasis, alopecia universalis, Behcet's disease, chronic fatigue, dysautonomia, endometriosis, interstitial cystitis, neuromyotonia, scleroderma, or vulvodynia.
[0100] In one embodiment, the inflammatory disease is asthma, appendicitis, blepharitis, bronchiolitis, bronchitis, bursitis, cervicitis, cholangitis, cholecystitis, colitis, conjunctivitis, cystitis, dacry- oadenitis, dermatitis, dermatomyositis, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibrositis, gastritis, gastroenteritis, hepatitis, hidradenitis suppurativa, laryngitis, mastitis, meningitis, myelitis myocarditis, myositis, nephritis, oophoritis, orchitis, osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis, pneumonitis, pneumonia, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis, synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, or vulvitis.
[0101] The following examples further illustrate the invention but are not to be construed as limiting its scope.
Examples:
[0102] Methods of Measurement and Analyses
[0103] X-Ray Powder Diffraction (XRPD):
[0104] Powder diffractograms were collected using X-ray powder diffractometer (PANalytical X’Pert PRO MPD, Almelo, NL) with Cu Ka radiation (X = 1.5418 A) at 45 kV and 40 mA and X' Celerator detector. Measurement was performed in the 2Theta range from 3 to 32.5°, with step size 0.033° and integration time 500 s.
[0105] Differential Scanning Calorimetry (DSC):
[0106] DSC measurements were performed on DSC 1 Mettler Toledo. 3 mg of sample was weighted in 40 pL aluminum crucibles with perforated lid. Sample was heated with linear heating rate 10 K/min up to 190 °C in the flow of nitrogen, 40 mL/min.
[0107] Scanning electron microscope (SEM):
[0108] Particle morphology images were collected by FEG Carl Zeiss ULTRA plus scanning electron microscope using Evemhart-Thomley secondary electron detector at 3. 1 mm working distance, 1 kV EHT and 30 pm aperture size.
[0109] Intrinsic dissolution rate (IDR):
[0110] The analyses were performed using USP Dissolution Apparatus 2 (paddles) with fixed-disk system. The compressed API (200 mg/1 min/1 ton) was exposed to acidic media for one hour under constant conditions (surface area 0.5 cm2, 10 mM HC1, 900 ml, 37 °C, 100 rpm). The samples were withdrawn after 5, 10, 15, 20, 30, 45, 60 minutes and analyzed with HPLC system. IDR was calculated using zero-order linear fit through the experimental data.
Example 1:
[0111] Ibrutinib (50g) was dissolved in methanol (750 m ) at 55 °C. Solution was filtered and cooled to 25 to 30 °C. During stirring cold water (1125 m ) at 15-20 °C was added in 2 hours. After addition, temperature was below 29 °C and crystallization occurred. Suspension was cooled to 5-10 °C and stirred for 4 hours. Material vas filtered and rinsed with chilled water. Wet material was suspended in methanol : water mixture (8V:2V) and stirred for 4 hours. Suspension was filtered and so obtained material was dried in vacuum dryer at 30 °C. Dried product (36 g) moisture content was 0.26% and content of residual methanol was below limit of detection.
Example 2:
[0112] Ibrutinib (50g) was dissolved in methanol (500 mb) at 55 °C. Solution was filtered and cooled to 30-35 °C. During stirring water (150 mb) at 20°C and seeding crystals (1500 mg), obtained by the Example 1, were added into the mixture at temperature 33 °C. East lot of water (600 mb) at 20 °C was added in 2 hours. After addition temperature was below 30 °C. Suspension was cooled to 5-10 °C and stirred for 4 hours. Material was filtered and rinsed with chilled water. Wet material was suspended in methanol : water mixture (8V:2V) and stirred for 4 hours. Suspension was filtered and so obtained material was dried in vacuum dryer at 30 °C. Dried product (37 g) moisture content was 0.27% and content of residual methanol was below limit of detection.
Example 3:
[0113] Ibrutinib (35g) was dissolved in methanol (350 mb) at 55 °C. Solution was filtered and cooled to 30-35 °C. During stirring water (70 mb) at 5-10°C and seeding crystals (350 mg) were added into the mixture at temperature 32 °C. East lot of water (455 mb) at 20 °C was added in 1 hour. After addition temperature was 30 °C. Suspension was cooled to 5-10 °C and stirred for 4 hours. Material was filtered and rinsed with chilled water and so obtained material was dried in vacuum dryer at 30 °C. Dried product (29.5 g grams) moisture content was 0.46% and content of residual methanol was below limit of detection.
Example 4:
[0114] Ibrutinib (50g) was dissolved in mixture of methanol (500 mb) and water (100 mb) at 52 °C. Clear solution was filtered through 0.5 urn filter, cooled to 30 °C and seeding crystals of form KI (500 mg) were added. After seeding suspension was left to crystallize for 30 minutes followed by heating of suspension to 35 °C over 2 hours. After 35 °C was reached suspension was stirred for additional 2 hours. Preheated water at 33 °C (650 mb) was gradually added into the suspension over 1 hour. Suspension was stirred for 2 hour at 35 °C and material was filtered and dried in vacuum try dryer at 30 °C under vacuum of 100 mbar and nitrogen flow. Dried product (44.3 g) moisture content was 0.31% and content of residual methanol was below limit of detection.
Example 5:
[0115] Results of intrinsic dissolution rate (IDR) analysis for the crystalline Form KI of ibrutinib and the crystalline Form A of ibrutinib are presented in the Table here below:
Figure imgf000027_0001

Claims

Patent claims:
1. A crystalline Form KI of ibrutinib characterized by X-ray powder diffraction (XRPD) pattern having characteristic peaks at 5.3±0.1°, 8.8±0.1°, 11.7±0.1°, 13.1±0.1°, 14.9±0.1°, and 16.8±0,l° 2Theta.
2. The crystalline Form KI of ibrutinib according to claim 1 characterized by X-ray powder diffraction (XRPD) pattern having additional characteristic peaks at 11.2±0.1°, 15.2±0.1°, 18.5±0.1° 2Theta.
3. The crystalline Form KI of ibrutinib according to any of claims 1 or claim 2 characterized by X-ray powder diffraction (XRPD) pattern having additional characteristic peaks at 20.1±0.1°, 21.7±0.1° and 23.8±0.1° 2Theta.
4. The crystalline Form KI of ibrutinib according to any one of claims 1 to 3 characterized by a DSC thermogram having an endothermic peak at about 128±3 °C.
5. The crystalline Form KI of ibrutinib according to any one of claims 1 to 4 characterized by mainly spherical agglomerates composed of plate-like primary particles, fused from the center outwards.
6. A process for preparing the crystalline Form KI of ibrutinib according to any one of claims 1 to 5 comprising the following steps: a) obtaining a solution of ibrutinib in alcohol, preferably C1-C5 alcohol, more preferably methanol; b) cooling the solution obtained in step a) to a temperature 20 °C to 50 °C, preferably from 20 °C to 45 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) adding a water having a temperature from 5 to 35 °C, preferably from 5 to 25 °C, more preferably from 10 °C to 25 °C; d) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; e) optionally, adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; f) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; g) optionally, stirring; and h) isolating crystalline material. The process according to any one of claim 6, wherein in step c) a ratio between alcohol and water is from 2: 1 to 1:4, preferably from 1.5: 1 to 1:3, more preferably from 1: 1 to 1:2, most preferably 1: 1.5, and wherein a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5. A process for preparing the crystalline Form KI of ibrutinib according to any one of claims 1 to 5 comprising the following steps: a) obtaining a solution of ibrutinib in a mixture of alcohol, preferably C1-C5 alcohol, more preferably methanol, and water; b) cooling the solution obtained in step a) to a temperature from 0 °C to 40 °C, preferably 15 °C to 35 °C, more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; c) optionally, adjusting a temperature of the solution obtained in step c) to a temperature from 15 °C to 45 °C, more preferably from 15 °C to 40 °C, even more preferably from 20 °C to 35 °C, even more preferably from 25 °C to 35 °C, most preferably from 25 °C to 30 °C; d) adding the second portion of water having a temperature from 25 °C to 45 °C, preferably from 30 °C to 40 °C, more preferably from 30 °C to 35 °C; e) optionally, cooling a suspension to a temperature from 0 °C to 15 °C, preferably to a temperature from 5 °C to 10 °C; f) optionally, stirring; and g) isolating crystalline material. The process according to claim 8, wherein in step a) a volume ratio between alcohol and water is from 10 : 1 to 1: 1, preferably from 8 : 1 to 2 : 1 , more preferably from 6 : 1 to 4 : 1 , most preferably 5: 1, and wherein a volume ratio between alcohol and water in the mixture obtained in step e) is from 2: 1 to 1:3, preferably from 1.5: 1 to 1:2, more preferably from 1: 1 to 1: 1.5. The process according to any one of claims 6 to 9, wherein the seed crystals of crystalline Form KI of ibrutinib are used.
PCT/EP2023/066201 2022-06-17 2023-06-16 Crystalline form of ibrutinib WO2023242384A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SIP-202200096 2022-06-17
SI202200096 2022-06-17

Publications (1)

Publication Number Publication Date
WO2023242384A1 true WO2023242384A1 (en) 2023-12-21

Family

ID=86904121

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/066201 WO2023242384A1 (en) 2022-06-17 2023-06-16 Crystalline form of ibrutinib

Country Status (1)

Country Link
WO (1) WO2023242384A1 (en)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039218A2 (en) 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
CN103694241A (en) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Novel crystal form A of PCI-32765 and preparation method thereof
CN103923084A (en) 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 Several new crystal forms and preparation methods thereof
WO2015145415A2 (en) 2014-03-27 2015-10-01 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
WO2016025720A1 (en) 2014-08-14 2016-02-18 Assia Chemical Industries Ltd. Solid state forms of ibrutinib
WO2016079216A1 (en) 2014-11-20 2016-05-26 Sandoz Ag Physical forms of ibrutinib, a bruton's kinase inhibitor
CN105646498A (en) 2016-03-01 2016-06-08 孙霖 Crystal form F of ibrutinib and preparation method
CN105646484A (en) 2016-03-01 2016-06-08 孙霖 Crystal form B and preparation method
WO2016115356A1 (en) 2015-01-14 2016-07-21 Pharmacyclics Llc Synthesis of a bruton's tyrosine kinase inhibitor
WO2016139588A1 (en) 2015-03-03 2016-09-09 Dr. Reddy's Laboratories Limited Polymorphs of ibrutinib
WO2016160604A1 (en) 2015-03-27 2016-10-06 Pharmacyclics Llc Co-crystals of a bruton's tyrosine kinase inhibitor
WO2016160598A1 (en) 2015-03-27 2016-10-06 Pharmacyclics Llc Solvated forms of a bruton's tyrosine kinase inhibitor
WO2017029586A1 (en) 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Crystalline forms of ibrutinib
WO2017174044A1 (en) * 2016-04-06 2017-10-12 Zentiva, K.S. Solid forms of ibrutinib

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039218A2 (en) 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
CN103694241A (en) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Novel crystal form A of PCI-32765 and preparation method thereof
WO2015081180A1 (en) 2013-11-27 2015-06-04 Crystal Pharmatech Inc. Crystalline form i of ibrutinib
CN103923084A (en) 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 Several new crystal forms and preparation methods thereof
WO2015145415A2 (en) 2014-03-27 2015-10-01 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
WO2016025720A1 (en) 2014-08-14 2016-02-18 Assia Chemical Industries Ltd. Solid state forms of ibrutinib
WO2016079216A1 (en) 2014-11-20 2016-05-26 Sandoz Ag Physical forms of ibrutinib, a bruton's kinase inhibitor
WO2016115356A1 (en) 2015-01-14 2016-07-21 Pharmacyclics Llc Synthesis of a bruton's tyrosine kinase inhibitor
WO2016139588A1 (en) 2015-03-03 2016-09-09 Dr. Reddy's Laboratories Limited Polymorphs of ibrutinib
WO2016160604A1 (en) 2015-03-27 2016-10-06 Pharmacyclics Llc Co-crystals of a bruton's tyrosine kinase inhibitor
WO2016160598A1 (en) 2015-03-27 2016-10-06 Pharmacyclics Llc Solvated forms of a bruton's tyrosine kinase inhibitor
WO2017029586A1 (en) 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Crystalline forms of ibrutinib
CN105646484A (en) 2016-03-01 2016-06-08 孙霖 Crystal form B and preparation method
CN105646498A (en) 2016-03-01 2016-06-08 孙霖 Crystal form F of ibrutinib and preparation method
WO2017174044A1 (en) * 2016-04-06 2017-10-12 Zentiva, K.S. Solid forms of ibrutinib

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZVONICEK ET AL.: "Ibrutinib Polymorphs: Crystallographic Study", CRYST. GROWTH DES., vol. 18, no. 3, 7 March 2018 (2018-03-07), US, pages 1315 - 1326, XP055523340, ISSN: 1528-7483, DOI: 10.1021/acs.cgd.7b00923 *

Similar Documents

Publication Publication Date Title
US11919906B2 (en) Crystal form of ACP-196 and method of treatment thereof
TWI526440B (en) Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-(4-(4-ethyl-piperazin-1-yl)-phenylamino)-pyrimidin-4-yl}-1-methyl-urea and salts thereof
EP2791141B1 (en) Tofacitinib mono-tartrate salt
US10899770B2 (en) Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
JP2014221831A (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
US9540321B2 (en) Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
US10023566B2 (en) Dasatinib salts
CN113993853A (en) Solid state forms of chlorobenzoic acid and salts thereof
EP3156406A1 (en) Crystalline forms of ribociclib free base
WO2010059913A2 (en) Preparation of rasagiline and salts thereof
US7977478B2 (en) Polymorphic forms of vardenafil
US8604194B2 (en) Salts of O-desmethyl-venlafaxine
US20190211008A1 (en) Solid state forms of palbociclib dimesylate
WO2011009634A2 (en) Process for producing fingolimod salts
US20180230097A1 (en) Process for preparation of apremilast and novel polymorphs thereof
EP1499581A1 (en) Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
CN1980666B (en) Process for preparing atazanavir bisulfate and novel forms
WO2023242384A1 (en) Crystalline form of ibrutinib
AU2016350219B2 (en) Innovative preparation and crystallization of iosimenol
EP2262758A2 (en) O-desmethylvenlafaxine salts
EP3553067A1 (en) Polymorph of sodium neridronate and preparation process thereof
CN114026088A (en) Crystalline forms of a JAK2 inhibitor
EP3771715A1 (en) Crystalline forms of baricitinib
WO2010131118A2 (en) Polymorphs of etravirine and processes for preparation thereof
WO2017029408A1 (en) Solid state forms of sofosbuvir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23733304

Country of ref document: EP

Kind code of ref document: A1